130 related articles for article (PubMed ID: 19712620)
1. Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments.
Bover R; Pérez-Gómez F; Maluenda MP; Asenjo S; Pérez-Saldaña R; Igea A; Suárez M; Coleto D; Fernández C
Rev Esp Cardiol; 2009 Sep; 62(9):992-1000. PubMed ID: 19712620
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
[TBL] [Abstract][Full Text] [Related]
3. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Alvarez-Sabín J; Quintana M; Santamarina E; Maisterra O
Cerebrovasc Dis; 2014; 37(3):181-7. PubMed ID: 24503927
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T;
Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Kalantzi KI; Ntalas IV; Chantzichristos VG; Tsoumani ME; Adamopoulos D; Asimakopoulos C; Bourdakis A; Darmanis P; Dimitriadou A; Gkiokas S; Ipeirotis K; Kitikidou K; Klonaris I; Kostaki A; Logothetis D; Mainas K; Mais T; Maragiannis A; Martiadou K; Mavronasos K; Michelongonas I; Mitropoulos D; Papadimitriou G; Papadopoulos A; Papaioakeim M; Sofillas K; Stabola S; Stefanakis E; Stergiou D; Thoma M; Zenetos A; Zisekas S; Goudevenos JA; Panagiotakos DB; Tselepis AD
Curr Vasc Pharmacol; 2019; 17(6):635-643. PubMed ID: 29866011
[TBL] [Abstract][Full Text] [Related]
6. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Culebras A; Rotta-Escalante R; Vila J; Domínguez R; Abiusi G; Famulari A; Rey R; Bauso-Tosselli L; Gori H; Ferrari J; Reich E;
Neurology; 2004 Apr; 62(7):1073-80. PubMed ID: 15079004
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
[TBL] [Abstract][Full Text] [Related]
8. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
[TBL] [Abstract][Full Text] [Related]
11. Triflusal for preventing serious vascular events in people at high risk.
Costa J; Ferro JM; Matias-Guiu J; Alvarez-Sabin J; Torres F
Cochrane Database Syst Rev; 2005 Jul; (3):CD004296. PubMed ID: 16034926
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease].
Matías-Guiu J; Alvarez-Sabín J; Codina A
Rev Neurol; 1997 Nov; 25(147):1669-72. PubMed ID: 9484514
[TBL] [Abstract][Full Text] [Related]
13. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial.
Aramendi JI; Mestres CA; Martinez-León J; Campos V; Muñoz G; Navas C
Eur J Cardiothorac Surg; 2005 May; 27(5):854-60. PubMed ID: 15848326
[TBL] [Abstract][Full Text] [Related]
14. Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial.
Pérez-Gómez F; Salvador A; Zumalde J; Iriarte JA; Berjón J; Alegría E; Almería C; Bover R; Herrera D; Fernández C
Eur Heart J; 2006 Apr; 27(8):960-7. PubMed ID: 16330464
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentre F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
Cerebrovasc Dis; 2001; 12(3):245-52. PubMed ID: 11641591
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
[TBL] [Abstract][Full Text] [Related]
18. The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.
Golive A; May HT; Bair TL; Jacobs V; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
Am J Cardiol; 2017 Jul; 120(1):75-82. PubMed ID: 28483209
[TBL] [Abstract][Full Text] [Related]
19. Platelet aggregation in different antithrombotic regimens. Possible proaggregant effect of low level oral anticoagulation.
Perez Gomez F; Lourenzo PI; Companion J; Escriba A; Perez Saldaña D; Guillén M; Vargas E; S-Harguindey L
Rev Port Cardiol; 2002 May; 21(5):541-51. PubMed ID: 12174518
[TBL] [Abstract][Full Text] [Related]
20. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.
Murdoch D; Plosker GL
Drugs; 2006; 66(5):671-92. PubMed ID: 16620146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
